Use of big data for drug development and for public and personal health and care

Lada Leyens, Matthias Reumann, Nuria Malats, Angela Brand

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalGenetic Epidemiology
Volume41
Issue number1
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Public Health
Drug Discovery
Delivery of Health Care
Pharmaceutical Preparations
Explosions
Drug Monitoring
Policy Making
Information Storage and Retrieval
Social Justice
Health Personnel
Epidemiology
Research Personnel
Health
Clinical Decision-Making

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Genetics(clinical)

Cite this

Leyens, Lada ; Reumann, Matthias ; Malats, Nuria ; Brand, Angela. / Use of big data for drug development and for public and personal health and care. In: Genetic Epidemiology. 2017 ; Vol. 41, No. 1. pp. 51-60.
@article{5574241a55f84ee8a74b882579374f6a,
title = "Use of big data for drug development and for public and personal health and care",
abstract = "The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.",
author = "Lada Leyens and Matthias Reumann and Nuria Malats and Angela Brand",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/gepi.22012",
language = "English",
volume = "41",
pages = "51--60",
journal = "Genetic Epidemiology",
issn = "0741-0395",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Use of big data for drug development and for public and personal health and care. / Leyens, Lada; Reumann, Matthias; Malats, Nuria; Brand, Angela.

In: Genetic Epidemiology, Vol. 41, No. 1, 01.01.2017, p. 51-60.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of big data for drug development and for public and personal health and care

AU - Leyens, Lada

AU - Reumann, Matthias

AU - Malats, Nuria

AU - Brand, Angela

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.

AB - The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.

UR - http://www.scopus.com/inward/record.url?scp=85005925841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005925841&partnerID=8YFLogxK

U2 - 10.1002/gepi.22012

DO - 10.1002/gepi.22012

M3 - Article

C2 - 27873357

AN - SCOPUS:85005925841

VL - 41

SP - 51

EP - 60

JO - Genetic Epidemiology

JF - Genetic Epidemiology

SN - 0741-0395

IS - 1

ER -